A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy

To join this study, you would need to be at least 18 years old. You must have been diagnosed with hypertrophic cardiomyopathy (HCM), which is a condition where your heart muscle is thicker than usual. Your HCM might be causing symptoms that affect your daily life.

Specifically, for the 'obstructive' type of HCM, doctors will check if there's a certain level of blockage to blood flow from your heart. If you have the 'non-obstructive' type, they'll confirm there's no significant blockage. Your heart's pumping strength (ejection fraction) also needs to be at a certain level. If you're already taking other heart medications, these should have been at a steady dose for at least a month.

You wouldn't be able to join if you've recently taken a similar type of medication (an SGLT2 inhibitor) or had a bad reaction to one in the past. Also, if you're already taking certain other specific medications like digoxin or if you're involved in another medical study right now, you would not be eligible.

Taking part in this study would involve regular visits to the clinic over a period. You would be given study medication – either sotagliflozin or a placebo – to take regularly. Throughout the study, doctors and nurses would perform various assessments to monitor your health, how your heart is working, and how your symptoms are changing. These might include heart scans, blood tests, and questionnaires about how you're feeling and your daily activities. There will be initial screening appointments to see if you're a good fit, treatment periods where you take the medication, and follow-up appointments after the main treatment phase. The full duration of your involvement, including all visits and follow-up, would be fully explained by the study team.